Literature DB >> 19472296

Neuropsychological functioning and quality of life during the first year after completing chemotherapy for breast cancer.

Stephanie A Reid-Arndt1, Catherine Hsieh, Michael C Perry.   

Abstract

OBJECTIVE: Research has documented modest cognitive difficulties among women treated for breast cancer. The present study was designed to evaluate the effects of these subtle cognitive changes on quality of life after treatment.
METHODS: Data are presented from women breast cancer patients who completed neuropsychological tests and questionnaires regarding quality of life 6 and 12 months post-chemotherapy (n's=39 and 33). Neuropsychological test scores were examined for evidence of cognitive difficulties at each time point; repeated measures ANOVAs were used to identify changes over time. Regression analyses assessed relationships of quality of life outcomes with cognitive functioning, social support seeking, and fatigue.
RESULTS: Small percentages of participants (<20% across tests) evidenced deficits in delayed memory, processing speed, response inhibition, and verbal fluency (VF) at each time point. Reliable change index analyses suggested statistically reliable improvements in each cognitive domain for a modest portion of participants. Regressions revealed hesitation to seek social support and fatigue as the most consistent predictors of quality of life at 6 and 12 months post-chemotherapy. Cognitive complaints and VF difficulties were also significantly related to quality of life at 12 months.
CONCLUSIONS: In addition to confirming the importance of fatigue and social support in quality of life, these data offer preliminary indications that weaker VF skills and self-reported cognitive complaints may be associated with poorer functional outcomes among cancer survivors. Further research is needed to validate these potential relationships, which suggest that cognitive difficulties among cancer survivors may warrant monitoring and possible intervention. Copyright 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 19472296      PMCID: PMC2861143          DOI: 10.1002/pon.1581

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  39 in total

1.  The relation of the trail making test to organic brain damage.

Authors:  R M REITAN
Journal:  J Consult Psychol       Date:  1955-10

2.  Clinical significance: a statistical approach to defining meaningful change in psychotherapy research.

Authors:  N S Jacobson; P Truax
Journal:  J Consult Clin Psychol       Date:  1991-02

3.  A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function.

Authors:  Catherine E Jansen; Christine Miaskowski; Marylin Dodd; Glenna Dowling; Joel Kramer
Journal:  Cancer       Date:  2005-11-15       Impact factor: 6.860

4.  A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer.

Authors:  Angela Stewart; Catherine Bielajew; Barbara Collins; Matthew Parkinson; Eva Tomiak
Journal:  Clin Neuropsychol       Date:  2006-02       Impact factor: 3.535

5.  Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy.

Authors:  F S van Dam; S B Schagen; M J Muller; W Boogerd; E vd Wall; M E Droogleever Fortuyn; S Rodenhuis
Journal:  J Natl Cancer Inst       Date:  1998-02-04       Impact factor: 13.506

6.  Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma.

Authors:  S B Schagen; F S van Dam; M J Muller; W Boogerd; J Lindeboom; P F Bruning
Journal:  Cancer       Date:  1999-02-01       Impact factor: 6.860

7.  Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.

Authors:  M J Brady; D F Cella; F Mo; A E Bonomi; D S Tulsky; S R Lloyd; S Deasy; M Cobleigh; G Shiomoto
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

Review 8.  The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature.

Authors:  Marina G Falleti; Antonietta Sanfilippo; Paul Maruff; LeAnn Weih; Kelly-Anne Phillips
Journal:  Brain Cogn       Date:  2005-06-21       Impact factor: 2.310

9.  Cognitive deficits in patients with small cell lung cancer before and after chemotherapy.

Authors:  C A Meyers; K S Byrne; R Komaki
Journal:  Lung Cancer       Date:  1995-06       Impact factor: 5.705

10.  A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer.

Authors:  V Jenkins; V Shilling; G Deutsch; D Bloomfield; R Morris; S Allan; H Bishop; N Hodson; S Mitra; G Sadler; E Shah; R Stein; S Whitehead; J Winstanley
Journal:  Br J Cancer       Date:  2006-03-27       Impact factor: 7.640

View more
  35 in total

Review 1.  Evidence-based indicators of neuropsychological change in the individual patient: relevant concepts and methods.

Authors:  Kevin Duff
Journal:  Arch Clin Neuropsychol       Date:  2012-02-29       Impact factor: 2.813

Review 2.  Chemotherapy-related cognitive dysfunction.

Authors:  Jeffrey S Wefel; Sanne B Schagen
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

Review 3.  What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research.

Authors:  Annalynn M Williams; Clive S Zent; Michelle C Janelsins
Journal:  Br J Haematol       Date:  2016-07-08       Impact factor: 6.998

4.  Yoga and self-reported cognitive problems in breast cancer survivors: a randomized controlled trial.

Authors:  Heather M Derry; Lisa M Jaremka; Jeanette M Bennett; Juan Peng; Rebecca Andridge; Charles Shapiro; William B Malarkey; Charles F Emery; Rachel Layman; Ewa Mrozek; Ronald Glaser; Janice K Kiecolt-Glaser
Journal:  Psychooncology       Date:  2014-10-21       Impact factor: 3.894

Review 5.  Chemobrain: a critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy.

Authors:  Xiao-Min Wang; Brian Walitt; Leorey Saligan; Agnes F Y Tiwari; Chi Wai Cheung; Zhang-Jin Zhang
Journal:  Cytokine       Date:  2015-01-05       Impact factor: 3.861

6.  Social enrichment attenuates chemotherapy induced pro-inflammatory cytokine production and affective behavior via oxytocin signaling.

Authors:  William H Walker; O Hecmarie Meléndez-Fernández; Jordan L Pascoe; Ning Zhang; A Courtney DeVries
Journal:  Brain Behav Immun       Date:  2020-07-29       Impact factor: 7.217

Review 7.  Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults.

Authors:  Jeffrey S Wefel; Shelli R Kesler; Kyle R Noll; Sanne B Schagen
Journal:  CA Cancer J Clin       Date:  2014-12-05       Impact factor: 508.702

8.  Early manifestation of mild cognitive impairment in B-cell non-Hodgkin's lymphoma patients receiving CHOP and rituximab-CHOP chemotherapy.

Authors:  Mohd Ashif Khan; Kamlesh Garg; Dinesh Bhurani; Nidhi Bharal Agarwal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-08-27       Impact factor: 3.000

9.  Relaxation acupressure reduces persistent cancer-related fatigue.

Authors:  Suzanna M Zick; Sara Alrawi; Gary Merel; Brodie Burris; Ananda Sen; Amie Litzinger; Richard E Harris
Journal:  Evid Based Complement Alternat Med       Date:  2010-09-02       Impact factor: 2.629

10.  The Feasibility of Using Metacognitive Strategy Training to Improve Cognitive Performance and Neural Connectivity in Women with Chemotherapy-Induced Cognitive Impairment.

Authors:  Timothy J Wolf; Meghan Doherty; Dorina Kallogjeri; Rebecca S Coalson; Joyce Nicklaus; Cynthia X Ma; Bradley L Schlaggar; Jay Piccirillo
Journal:  Oncology       Date:  2016-07-23       Impact factor: 2.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.